Specifically, in an NAFLD mouse model, butyrate alleviated hepatic steatosis by enhancing hepatic glucagon-like peptide-1 (GLP-1) sensitivity via increased GLP-1 receptor (GLP-1R) expression. Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.